Enliven Therapeutics, Inc. Quarterly Income Tax Expense (Benefit) in USD from Q3 2023 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Enliven Therapeutics, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q3 2023 to Q3 2024.
  • Enliven Therapeutics, Inc. Income Tax Expense (Benefit) for the quarter ending September 30, 2024 was $0.000.
  • Enliven Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2023 was $0.000.
Income Tax Expense (Benefit), Quarterly (USD)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $0 $0 Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-13
Q2 2024 $232K Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-13
Q3 2023 $0 Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.